ALX Oncology (NASDAQ:ALXO) Trading Up 9.1%

ALX Oncology Holdings Inc. (NASDAQ:ALXO)’s stock price was up 9.1% during trading on Tuesday . The stock traded as high as $15.53 and last traded at $15.53. Approximately 205,332 shares changed hands during mid-day trading, a decline of 52% from the average daily volume of 430,118 shares. The stock had previously closed at $14.23.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on ALXO shares. HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of ALX Oncology in a research report on Wednesday, April 10th. Stifel Nicolaus reiterated a “hold” rating and issued a $14.00 target price (up previously from $10.00) on shares of ALX Oncology in a research report on Friday, March 8th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of ALX Oncology in a research report on Friday, April 12th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, ALX Oncology presently has an average rating of “Moderate Buy” and a consensus price target of $18.83.

ALX Oncology Trading Up 4.0 %

The company’s 50 day moving average price is $13.61 and its 200 day moving average price is $12.21. The company has a market cap of $843.50 million, a price-to-earnings ratio of -4.50 and a beta of 1.58. The company has a debt-to-equity ratio of 0.05, a quick ratio of 5.24 and a current ratio of 5.24.

ALX Oncology (NASDAQ:ALXO) last announced its quarterly earnings results on Thursday, March 7th. The company reported ($0.93) EPS for the quarter, missing the consensus estimate of ($0.84) by ($0.09). Research analysts anticipate that ALX Oncology Holdings Inc. will post -3.33 EPS for the current year.

Insider Activity at ALX Oncology

In related news, insider Jaume Pons sold 50,000 shares of the firm’s stock in a transaction on Tuesday, April 16th. The shares were sold at an average price of $14.20, for a total value of $710,000.00. Following the transaction, the insider now directly owns 604,205 shares in the company, valued at approximately $8,579,711. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, CEO Jason Lettmann acquired 4,400 shares of the company’s stock in a transaction dated Thursday, March 14th. The shares were bought at an average price of $11.31 per share, for a total transaction of $49,764.00. Following the acquisition, the chief executive officer now owns 171,620 shares in the company, valued at approximately $1,941,022.20. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Jaume Pons sold 50,000 shares of the business’s stock in a transaction dated Tuesday, April 16th. The stock was sold at an average price of $14.20, for a total transaction of $710,000.00. Following the transaction, the insider now owns 604,205 shares in the company, valued at approximately $8,579,711. The disclosure for this sale can be found here. 50.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On ALX Oncology

Large investors have recently modified their holdings of the stock. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of ALX Oncology during the fourth quarter worth approximately $28,000. China Universal Asset Management Co. Ltd. lifted its position in shares of ALX Oncology by 445.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 5,762 shares of the company’s stock worth $86,000 after purchasing an additional 4,706 shares in the last quarter. SG Americas Securities LLC acquired a new position in shares of ALX Oncology during the third quarter worth approximately $48,000. Forefront Analytics LLC acquired a new position in shares of ALX Oncology during the third quarter worth approximately $66,000. Finally, Dynamic Technology Lab Private Ltd bought a new stake in shares of ALX Oncology during the fourth quarter worth approximately $215,000. 97.97% of the stock is currently owned by institutional investors and hedge funds.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.